JP Morgan Chase’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

JP Morgan Chase’s Portfolio SLGC Stock Details SLGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-193,865	Closed	-$490K	–	8098
2023 Q4	$490K	Buy	193,865 +2,345	+1%	+$5.46K	﹤0.01%	4811
2023 Q3	$458K	Sell	191,520 -22,955	-11%	-$50.8K	﹤0.01%	4535
2023 Q2	$495K	Sell	214,475 -19,283	-8%	-$54.4K	﹤0.01%	4502
2023 Q1	$596K	Buy	233,758 +79,583	+52%	+$228K	﹤0.01%	4384
2022 Q4	$387K	Buy	154,175 +15,832	+11%	+$44.2K	﹤0.01%	4679
2022 Q3	$401K	Buy	138,343 +3,999	+3%	+$16.8K	﹤0.01%	4593
2022 Q2	$608K	Buy	+134,344	New	+$799K	﹤0.01%	4437
2021 Q4	–	Sell	-24,314	Closed	-$301K	–	7073
2021 Q3	$301K	Buy	+24,314	New	+$274K	﹤0.01%	5015

JP Morgan Chase's SLGC Position: Q1 2024 in Review

JP Morgan Chase sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 193,865 shares — an estimated $490K sold.

JP Morgan Chase first reported a position in SLGC in Q3 2021 and held it in 8 quarters. The position peaked at $608K in Q2 2022. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

JP Morgan Chase reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 193,865 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $490K.
JP Morgan Chase first reported a position in SomaLogic, Inc. Class A Common Stock in Q3 2021 and held it in 8 quarters.
JP Morgan Chase's SomaLogic, Inc. Class A Common Stock position peaked at $608K in Q2 2022.
0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.